The Tough Tech problem we are solving
The COVID-19 pandemic exposed critical vulnerabilities in global biomanufacturing: insufficient capacity, scalability risks, and decades-old bottlenecks that stifle innovation in a trillion-dollar market spanning mAbs, vaccines, and bio-therapeutics. Developers face lengthy process optimization, sky-high capex, and inherent risks that delay animal testing, clinical trials, and market entry by years, leaving life-saving therapies trapped in labs and biodefense unprepared for future threats.
About our solution
Evoworks Bio revolutionizes bioproduction scaling with a proprietary platform that obsoletes legacy workflows—eliminating scalability risks, slashing time-to-market by 1-2 years, and cutting costs up to 10x. By streamlining fermentation and process development, we empower hundreds of new therapeutics annually to rapidly advance from discovery to full manufacturing, accelerating global health security and unlocking bioproduction's full potential.